Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.

@article{Romanowski2000EfficacyAS,
  title={Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.},
  author={Barbara Romanowski and Fred Y. Aoki and Alain Y Martel and Edward Lavender and John E. Parsons and Robin L. Saltzman},
  journal={AIDS},
  year={2000},
  volume={14 9},
  pages={1211-7}
}
OBJECTIVE To compare the efficacy and safety of 7 days' treatment with famciclovir 500 mg twice a day versus acyclovir 400 mg five times a day, for mucocutaneous herpes simplex virus (HSV) infection in HIV-infected individuals. DESIGN Randomized, double-blind, parallel-group study to demonstrate equivalence for the primary efficacy parameter. SETTING Forty-eight hospital-based or specialist public-health clinics in 12 countries. PATIENTS Two-hundred and ninety-three HIV-positive patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Sexually transmitted diseases treatment guidelines, 2015.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports • 2015

Sexually transmitted diseases treatment guidelines, 2010.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports • 2010

Management of oral lesions in HIV-positive patients.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics • 2007

Similar Papers

Loading similar papers…